| Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol - Safety and Efficacy Trial | Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol - Safety and Efficacy Trial | EUCTR2008-000168-18-DK |
| "Clinical evaluation of the 3 allergens: Methyldibromoglutharonitrile, Parthenolide and Goldsodiumthiosulphate for ""TRUE Test Panel 3"" - a phase II, dose-response study." | "Clinical evaluation of the 3 allergens: Methyldibromoglutharonitrile, Parthenolide and Goldsodiumthiosulphate for ""TRUE Test Panel 3"" - a phase II, dose-response study." | EUCTR2004-004899-36-SE |
| Radioprotective effects of parthenolide lotion against skin injury caused by radiation in people with head and neck cancer | Radioprotective effects of parthenolide lotion against skin injury caused by radiation in people with head and neck cancer | ACTRN12625000456459 |
| Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate | Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for ”TRUE Test® Panel 3” – a Phase II, Dose-Response Study. | NCT00133341 |
